Search Page

1

Cite

Share

Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2.

Baldo A, Leunda A, Willemarck N, Pauwels K. Baldo A, et al. Among authors: pauwels k. Vaccines (Basel). 2021 May 3;9(5):453. doi: 10.3390/vaccines9050453. Vaccines (Basel). 2021. PMID: 34063733 Free PMC article. Review.

Cite

Share

2

Cite

Share

Engineering nucleases for gene targeting: safety and regulatory considerations.

Pauwels K, Podevin N, Breyer D, Carroll D, Herman P. Pauwels K, et al. N Biotechnol. 2014 Jan 25;31(1):18-27. doi: 10.1016/j.nbt.2013.07.001. Epub 2013 Jul 12. N Biotechnol. 2014. PMID: 23851284 Review.

Cite

Share

3

Cite

Share

General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination.

Baldo A, van den Akker E, Bergmans HE, Lim F, Pauwels K. Baldo A, et al. Among authors: pauwels k. Curr Gene Ther. 2013 Dec;13(6):385-94. doi: 10.2174/15665232113136660005. Curr Gene Ther. 2013. PMID: 24195604 Free PMC article. Review.

Cite

Share

4

Cite

Share

Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors.

Goossens M, Pauwels K, Willemarck N, Breyer D. Goossens M, et al. Among authors: pauwels k. Curr Gene Ther. 2013 Dec;13(6):413-20. doi: 10.2174/156652321306140103221941. Curr Gene Ther. 2013. PMID: 24397528 Free PMC article. Review.

Cite

Share

5

Cite

Share

Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination.

Verheust C, Goossens M, Pauwels K, Breyer D. Verheust C, et al. Among authors: pauwels k. Vaccine. 2012 Mar 30;30(16):2623-32. doi: 10.1016/j.vaccine.2012.02.016. Epub 2012 Feb 17. Vaccine. 2012. PMID: 22342706 Free article. Review.

Cite

Share

6

Cite

Share

State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations.

Pauwels K, Gijsbers R, Toelen J, Schambach A, Willard-Gallo K, Verheust C, Debyser Z, Herman P. Pauwels K, et al. Curr Gene Ther. 2009 Dec;9(6):459-74. doi: 10.2174/156652309790031120. Curr Gene Ther. 2009. PMID: 20021330 Review.

Cite

Share

7

Cite

Share

Contributions from scientific research to the risk assessment of GMOs. Lessons learned from a symposium held in Brussels, Belgium, 21-22 October 2010.

Pauwels K, Breyer D, De Schrijver A, Goossens M, Herman P. Pauwels K, et al. Environ Biosafety Res. 2010 Jul-Sep;9(3):113-21. doi: 10.1051/ebr/2011108. Epub 2011 Aug 19. Environ Biosafety Res. 2010. PMID: 21851803 Free article. Review. No abstract available.

Cite

Share

8

Cite

Share

Genetic modification through oligonucleotide-mediated mutagenesis. A GMO regulatory challenge?

Breyer D, Herman P, Brandenburger A, Gheysen G, Remaut E, Soumillion P, Van Doorsselaere J, Custers R, Pauwels K, Sneyers M, Reheul D. Breyer D, et al. Among authors: pauwels k. Environ Biosafety Res. 2009 Apr-Jun;8(2):57-64. doi: 10.1051/ebr/2009007. Epub 2009 Oct 16. Environ Biosafety Res. 2009. PMID: 19833073 Free article.

Cite

Share

9

Cite

Share

The N-acetylglutamate synthase/N-acetylglutamate kinase metabolon of Saccharomyces cerevisiae allows co-ordinated feedback regulation of the first two steps in arginine biosynthesis.

Pauwels K, Abadjieva A, Hilven P, Stankiewicz A, Crabeel M. Pauwels K, et al. Eur J Biochem. 2003 Mar;270(5):1014-24. doi: 10.1046/j.1432-1033.2003.03477.x. Eur J Biochem. 2003. PMID: 12603335 Free article.

Cite

Share